Press Releases
December 15, 2006
Exclusive Berlin Conference Catalysed New Partnerships Between Pharma & Biotech Companies
European Small & Medium-sized biopharmaceutical companies had the opportunity to network with counterparts from the larger pharmaceutical companies at a private Business Development Event, organised by the industry associations European Biopharmaceutical Enterprises (EBE) and BIO Deutschland.
Despite the increasing costs, falling output and failure of some new technologies in the European biotechnology R&D landscape, in recent years the start-up rate of new enterprises has increased and the growth of existing European companies has accelerated. Alliances with midsize and big pharma have become a more and more important aspect in European biotech business plans.
With this in mind, the event reviewed how to make European biotech companies more attractive to US and global partners and what are the successful strategies for the future of European biopharmaceutical companies.
Executives from key biotech, pharmaceutical companies, private equity and VC firms shared their experience, concrete case-studies and advice on what should or should not be done in developing biotech company businesses. The conference also analysed the business management and financing practices in the US versus Europe, new exit trends in those regions and the different business models available.
"Biotechnology is not only important for the economy" said Dr. Peter Heinrich, CEO MediGene AG, President BIO Deutschland and EBE Board Member, "not only because of the thousands of people that we employ, but is also essential to the larger pharmaceutical companies which use biotech companies as a source for innovation and finally, let"s not forget, the patients waiting for novel medicines."
The event attracted more than 85 CEOs and senior executives from (bio)pharmaceutical companies, private equity and venture capital companies from around Europe and USA. The exclusive setting of the conference helped participants learn, network and do business. Further to the extremely positive feedback received from attendees, EBE and BIO Deutschland are planning to hold a 2nd edition in 2007, in Germany.
307 word / 2.085 characters
NOTES TO EDITORS:
1. The conference was kindly sponsored by VISCARDI Group, The Trout Group, Roche, Genzyme and Nomura Code.
2. The Biotechnologie-Industrie-Organisation Deutschland (BIO Deutschland) with offices in Berlin is the independent organisation for German biotechnology companies. Founded in October 2004, BIO Deutschland currently has more than 120 member companies. To support its members BIO Deutschland is active on a wide range of measures like lobbying, public relations, or offering business development opportunities.
3. As the voice of biopharmaceuticals in Europe, European Biopharmaceutical Enterprises (EBE) promotes a favourable scientific, business and regulatory environment allowing companies of all sizes to successfully research, develop and market new healthcare solutions derived from biotechnology for the benefit of patients and society. EBE has 65 member companies, including include large pharma groups, biotech companies and SMEs; and operates as specialised group within EFPIA.
4. The full programme is available at www.ebe-biopharma.org/force-download.php?file=/media/bd-conference1314_12_06 (15.12.06).pdf or at www.biodeutschland.org/bdconfer/bdconfer.php
Download printable image - Free use, please provide copy
September 4, 2006
BIO Deutschland Appoints Dr. Viola Bronsema as Managing Director
The Biotechnologie-Industrie-Organisation Deutschland (BIO Deutschland e.V.) is strengthening its political leverage in Berlin: As of October 1, 2006 Dr. Viola Bronsema will be the Managing Director of BIO Deutschland. Previously Ms Bronsema was Head of Communications at Roche Diagnostics GmbH, Mannheim.
Viola Bronsema received her Ph.D. at the Centre for Molecular Biology (ZMBH) at the University of Heidelberg, where she also worked as a research scientist for some years. In 1995 she received her PR consultant certificate, after which she worked for Cramer-Gesundheits-Consulting, Frankfurt. From 1998 onwards she was employed at the Press & Public Relations department of the German Cancer Research Center (DKFZ), Heidelberg, and in 2000 she moved to Lilly Pharma Holding GmbH, Bad Homburg, to act as Head of Press & Public Relations. As of 2002 she has worked for Roche Diagnostics GmbH, Mannheim, heading the communication activities for Germany and EMEA (Europe, Middle East and Africa). Since early 2003 she has also been the Managing Director of Stadtmarketing Mannheim GmbH.
Dr. Peter Heinrich, Chairman of the Board of BIO Deutschland and CEO of MediGene AG, Martinsried, commented on Dr. Viola Bronsema"s appointment to the association"s administrative office: "Thanks to the valuable support from the executive search firm Ray & Berndtson, BIO Deutschland"s Board was able to appoint Viola Bronsema - a highly competent and experienced Life Sciences personality - to reinforce our administrational office."
Viola Bronsema is looking forward to her new appointment in Berlin: "BIO Deutschland has achieved a lot in a very short period of time and I am convinced that we will succeed in the future to further improve the framework conditions for the Biotech location Germany, both nationally and internationally."
Together with BIO Deutschland"s Board and Dr. Pablo Serrano, Senior Manager of the association"s administrative office, Viola Bronsema will expand and reinforce the association’s activities. BIO Deutschland"s main fields of activity are the coordination of a joint positioning process, the creation of B2B plattforms and the political representation of its members" interest.
January 18, 2006
News
May 2009
Interdisciplinary Conference on the Promotion of Technology Transfer in Biotechnology //
BIO Deutschland’s Fourth Parliamentary Evening //
Statement by BIO Deutschland on the Amendment to Patent Law //
Presentation of the survey of companies by Ernst & Young and biotechnologie.de //
Critical Evaluation by BIO Deutschland to the Forthcoming Amendments to the Drug Law
April 2009
Comments by BIO Deutschland on the German Agriculture Minister’s Decisions on Plant Biotechnology //
Meet Investors and Pharmaceutical Companies: Business Development Conference in Munich //
Associations’ Statement on European Animal Welfare Guidelines //
International Events: Participation at the Europa-Bio GBE Meeting of National Teams
March 2009
Financial Crisis: Entrepreneurs and Financial Experts from the Biotech Sector Write to the Federal Government //
Support for the Association in the Recommendations by the Commission of Experts for Research and Innovation //
British-German Workshop on Stem Cells and Regenerative Medicine
February 2009
Genetic Diagnostics Law: Letter to the Federal Minister of Health, Ulla Schmidt //
Meeting of the Working Group on Health Policy in Munich //
British and Spanish Biotech Organisation to Attend this Year’s Business Development Conference on 24 and 25 June in Munich
January 2009
German BioRegions Council Joins BIO Deutschland //
Genetic Diagnostics Draft Law: Reading in the Bundestag (Lower House of the German Parliament) //
Revision of the Medication Law: Hearing at the German Federal Ministry of Health //
Animal Welfare: Meeting of Experts at the German Federal Ministry of Research //
Biosecurity: Meeting of Experts at the German Federal Ministry of Foreign Affairs //
Visit by the Chinese Delegation: Joint Working Group //
Eva Luise Köhler Receives Donation from the Biotech Industry